Cutting a new path

As gene editing starts to make headway, its first indications are informed by the path laid by gene therapies and other nucleic acid modalities. But drug developers think editing is poised to move far beyond those applications, and are eyeing infectious disease and regenerative medicine as areas where the technology could be best differentiated.

According to gene editing companies interviewed by BioCentury, the sector’s first disease areas were picked largely based on the ground broken for delivery vectors by the antisense and gene therapy fields. ...